Michael Davis

Davis Polk is advising Varagon Capital Partners, L.P. on its agreement to form a new strategic partnership with Aflac Global Investments and the extension of its existing strategic…

Davis Polk advised Crestview Partners on its minority investment in ICM Partners, LLC.Founded in 2004, Crestview is a value-oriented private equity firm focused on the middle market…

Davis Polk is advising Bertelsmann SE & Co. KGaA on its $675 million acquisition of the stake it did not hold in Penguin Random House. Bertelsmann acquired the remaining 25% stake held…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised an ad hoc group of lenders under a $347 million first-lien and a $140 million second-lien term loan credit facility of CTI Foods, LLC …

Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with the sale of substantially all of its assets to Currax Holdings LLC, an entity formed by affiliates of Highbridge…

Davis Polk is advising an ad hoc group of lenders (the “Ad Hoc Group”) under a $347 million first-lien and a $140 million second-lien term loan credit…

Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the United States Bankruptcy Code, entry into a “stalking horse” asset…

Davis Polk advised the initial purchasers in connection with a Regulation S offering by Zhenro Properties Group Limited of $150 million 10.5% senior notes due 2020 (to be consolidated and…

Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction, which is subject to customary closing conditions and the approval of…